Autologous MSC Therapy for Veterinary Use
Musculoskeletal disorders (e.g., osteoarthritis, tendonitis) in horses and companion animals
Pre-clinicalActive
Key Facts
Indication
Musculoskeletal disorders (e.g., osteoarthritis, tendonitis) in horses and companion animals
Phase
Pre-clinical
Status
Active
Company
About RevaTis
Revatis is a private, preclinical-stage biotech leveraging a proprietary platform to isolate and expand mesenchymal stem cells (MSCs) from a small muscle biopsy. Its core business model spans both therapeutic applications in veterinary medicine and a service/provider role for human biomedical research, including biobanking, organ-on-a-chip, and 3D bioprinting. Founded in 2015, the company operates with GMP-certified production, has an international footprint, and is built on strong IP from its academic founders. It is currently pre-revenue, focusing on technology development and partnership expansion.
View full company profile